Trading Update - 2009

Risultati record

Embargo fino alle 17.40 (ora del Belgio) - 21 gennaio 2010

Crescita molto marcata e solida redditivit? per il 2009

- Fatturato EUR 32,5 milioni
- EBITDA vicino a EUR 8 milioni
- Utile netto superiore a EUR 4,8 milioni

Seneffe - Belgio, 21 gennaio 2010, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) ha comunicato oggi il suo trading update relativo ai risultati del 2009, sulla base dei dati preliminari.

Principali dati operativi del 2009

Da un punto di vista operativo, ? opportuno mettere in luce i seguenti dati:

- In a growing number of emerging markets, the company encountered success in the promotion of its Temporary Brachytherapy MultiSource? solution - a world unique HDR (High Dose Rate) Co-60 afterloader equipment. This system allows for the efficient treatment of a number of different pathologies ranging from head, neck, brain or gynecological cancers. During the year 2009, the 100th hospital proceeded with the installation of a MultiSource?.

- Successful development of the group in Russia. Creation of a Russian joint venture, NanoBrachyTech, in association with RusNano, the State Fund of the Russian Federation. The JV, based in Moscow, will initially focus on innovative technologies for the treatment of cancer by brachytherapy. It is expected that this major development will yield up to EUR 20 million in revenues for the group over the life of the project.

- Towards the end of the year, the signature of a strategic alliance with Core Oncology, Inc. (USA) and currently one of the top four companies in the American market for Permanent Brachytherapy, represents another major project for IBt Bebig as this alliance could provide a unique opportunity to re-enter into a market that is roughly four times the size of the European market.

Preliminary Key Financial Results

Current reporting indicates that, boosted by a surprisingly strong fourth quarter, total sales for the year 2009 have reached an historical all-time high in the amount of EUR 32.5 million.

The source of revenues was evenly split between Permanent Brachytherapy and Temporary brachytherapy products. Approximately half of the total revenues were indeed generated by sales of I-125 (Iodine-125) radiotherapeutic implants, used for the treatment of early stage prostate cancer. The other half of the revenues related to sales of MultiSource? HDR Co-60 temporary brachytherapy equipments (usually referred to as afterloaders), Ru-106 (Ruthenium) ophthalmic plaques and therapy accessories. In addition, the total income was also boosted by revenues generated by the contracts signed in Russia earlier in the year.

Earnings before interest and taxes (EBIT) is reported to reach almost EUR 6 million for the year 2009, therefore more than doubling the amount booked in the previous year or EUR 2.4 million in 2008 (1).

On a Net Income basis, the company will also book its first annual Net Profit ever since IBt started its activities a little over than ten years ago. Net Profit for the year 2009 should exceed EUR 4.8 million compared to a net loss of EUR 2.7 million in 2008. This Net Profit will represent a margin exceeding 14% when expressed in proportion to revenues.

Finally, on the balance sheet side, IBt Bebig also ended up the year in a strong position with total cash exceeding EUR 9 million.

The company will provide its guidance for the year 2010 at the time of the release of the detailed financial report for the 2009 figures (on March 15, 2010).

Note (1): The comparability between the years 2009 and 2008 is somewhat reduced as the consolidation scope of the group was substantially modified (several acquisitions - Bebig GmbH and temporary brachytherapy activities - and divestitures, CurieMed bv.) during the course of the year 2008. The year 2009 is therefore the first full year in which the full benefit of the acquisitions is integrated and reported.

Control

The auditor has not reviewed any of the figures contained in this trading update.

Shareholders Calendar

The full set of Annual Results 2009 will be published by March 15, 2010
Trading Update 1Q-2010: by May 15, 2010
Annual General Assembly: June 7, 2010 (at 10:30 am)

About IBt Bebig

... Contributing to saving lives!

The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector.

The core business of the IBt Bebig group is the cancer treatment by radiation technology. Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed implant containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis. Depending on the application, the implant can take the shape of a plaque, a seed or a catheter. The precise positioning of the implant allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient's quality of life. Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.

The IBt Bebig group employs over 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India. Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).

Contact
Paul-Emmanuel Goethals
Head of Investor Relations & Communication
Tel: +32.64.520.808

E-mail: ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu

Copyright Hugin

Questo comunicato ? distribuito da Hugin. L'emittente ? l'unico responsabile per il contenuto del comunicato.

[CN#162378]